Editas might be benefiting from an uptick in interest regarding gene-editing stocks. Its lead therapy, EDIT-301, is designed to fight transfusion-dependent beta thalassemia and sickle cell disease.
Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results